The Protective Effects of Reineckia carnea Ether Fraction against Alzheimer’s Disease Pathology: An Exploration in Caenorhabditis elegans Models
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242216536 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Hai-Jun Fu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Sichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, School of Pharmacy, Southwest Medical University, Luzhou 646000, Chi…. Hauptthemen laut MEDLINE: Alzheimer Disease, Caenorhabditis elegans Proteins. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, The Science and Technology Planning Project of Sichuan Province, China, National Natural Science Foundation of China.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) presents a significant challenge to global healthcare systems, with current treatments offering only modest relief and often bringing unwanted side effects, necessitating the exploration of more effective and safer drugs. In this study, we employed the Caenorhabditis elegans (C. elegans) model, specifically the AD-like CL4176 strain expressing the human Aβ(1–42) protein, to investigate the potential of Reineckia carnea extract and its fractions. Our results showed that the Reineckia carnea ether fraction (REF) notably diminished the paralysis rates of CL4176 worms. Additionally, REF also attenuated the neurotoxicity effects prompted by Tau proteins in the BR5270 worms. Moreover, REF was observed to counteract the accumulation of Aβ and pTau proteins and their induced oxidative stress in C. elegans AD-like models. Mechanistic studies revealed that REF’s benefits were associated with the induction of autophagy in worms; however, these protective effects were nullified when autophagy-related genes were suppressed using RNAi bacteria. Together, these findings highlight Reineckia carnea ether fraction as a promising candidate for AD treatment, warranting further investigation into its autophagy-inducing components and their molecular mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.
- Central Nervous System Drug Key Laboratory of Sichuan Province, Luzhou 646000, China.
ORCID-Profile: Jian-Ming Wu, An-Guo Wu, Xiao-Gang Zhou
Förderung
- the National Natural Science Foundation of China
- The Science and Technology Planning Project of Sichuan Province, China
- National Natural Science Foundation of China
- Science and Technology Planning Project of Sichuan Province
- Luzhou Municipal People’s Government and Southwest Medical University
Zitieren
APA
Fu, H. J., Zhou, X. Y., Li, Y. P., Chen, X., He, Y. N., Qin, D. L., Yu, L., Yu, C. L., Wu, J. M., Wu, A. G., & Zhou, X. G. (2023). The Protective Effects of Reineckia carnea Ether Fraction against Alzheimer’s Disease Pathology: An Exploration in Caenorhabditis elegans Models. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242216536
Vancouver
Fu HJ, Zhou XY, Li YP, Chen X, He YN, Qin DL, et al. The Protective Effects of Reineckia carnea Ether Fraction against Alzheimer’s Disease Pathology: An Exploration in Caenorhabditis elegans Models. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242216536
BibTeX
@article{Fu2023,
author = {Fu, Hai-Jun and Zhou, Xing-Yue and Li, Ya-Ping and Chen, Xue and He, Yan-Ni and Qin, Da-Lian and Yu, Lu and Yu, Chong-Lin and Wu, Jian-Ming and Wu, An-Guo and Zhou, Xiao-Gang},
title = {The Protective Effects of Reineckia carnea Ether Fraction against Alzheimer’s Disease Pathology: An Exploration in Caenorhabditis elegans Models},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242216536}
}
EUVIMED